Deerfield Management Company, L.P. (Series C) Prelude Therapeutics Inc Transaction History
Deerfield Management Company, L.P. (Series C)
- $4.84 Billion
- Q1 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 4,133,000 shares of PRLD stock, worth $15.4 Million. This represents 0.4% of its overall portfolio holdings.
Number of Shares
4,133,000
Previous 4,133,000
-0.0%
Holding current value
$15.4 Million
Previous $17.6 Million
11.01%
% of portfolio
0.4%
Previous 0.43%
Shares
1 transactions
Others Institutions Holding PRLD
# of Institutions
59Shares Held
34.2MCall Options Held
200Put Options Held
0-
Orbimed Advisors LLC San Diego, CA10.9MShares$40.7 Million1.16% of portfolio
-
Baker Bros. Advisors LP New York, NY10.1MShares$37.8 Million0.61% of portfolio
-
Boxer Capital, LLC San Diego, CA2.57MShares$9.58 Million0.63% of portfolio
-
Black Rock Inc. New York, NY1.1MShares$4.09 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.02MShares$3.79 Million0.0% of portfolio
About Prelude Therapeutics Inc
- Ticker PRLD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,369,200
- Market Cap $136M
- Description
- Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...